Waukeshahealthinsurance.com-
–
The drug currently used to treat HIV has been found to significantly reduce the risk of infection, far more than the main alternative to pre-exposure prophylaxis, or PREP.
In a phase 3 clinical trial, 99.9% of participants who received twice-yearly injections of lencapavir for HIV prevention did not get an infection, the data showed. Drug maker Gilead Sciences.
Among 2,180 patients, there were only two cases – it reduced the risk of HIV infection by 96% and was 89% more effective than Truvada when taken once a day. The trial was not blinded early because it met its key endpoints, allowing lenacapavir to be given to all participants.
“Difficulties some people may have with taking the oral pill daily, including challenges with adherence and abstinence, have hindered uptake and adherence to long-term care, thereby blunting PrEP's impact on HIV prevention,” said Principal Onyama Ogbugu. to the trial investigator and director of the Yale Antiviral and Vaccines Research Program.
“The impressive efficacy demonstrated in the PURPOSE 2 trial, the potential benefit of twice-yearly injections, and the diversity of trial sites and participants demonstrate the potential impact of lenacapavir on new choices for PrEP worldwide to reduce the risk of HIV infection. This breakthrough It adds greatly to our tools to bring us closer to bringing about an AIDS-free generation.
Get Health's weekly newsletter
The PURPOSE 2 trial included cisgender men, transgender men, transgender women, and sexually active individuals aged 16 years or older who were sexually active with partners assigned at birth. There were 88 test sites in Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the United States.
Another trial showed that taking the long-acting lenacavir as pre-exposure prophylaxis can completely prevent HIV in women. Test data Published in July.
By A News release From the World Health Organization in July.
Gilead said it will use these trial data to start the drug approval process in more countries by the end of the year. According to the company, it plans to prioritize licensing in high-risk and low-income countries.